Monitoring and documentation of side effects from depot antipsychotic medication: An interdisciplinary audit of practice in a regional mental health service

Journal of Psychiatric and Mental Health Nursing

Volumn 19, Issue 5, 2012, Pages 395-401

  Cleary, A ^a   Walsh, F ^a   Connolly, H ^a   Hays, V ^a   Oluwole, B ^a   Macken, E ^a   Dowling, M ^b  

^a St Brigids Hospital   (Ireland)

^b NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

Antipsychotics; Audit; Depot; Mental health; Metabolic syndrome; Side effects

Indexed keywords

NEUROLEPTIC AGENT;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; DELAYED RELEASE FORMULATION; DOCUMENTATION; DRUG MONITORING; FEMALE; HUMAN; IRELAND; MALE; MEDICAL AUDIT; MENTAL DISEASE; MENTAL HEALTH SERVICE; MIDDLE AGED; MULTICENTER STUDY; RURAL HEALTH CARE;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; COMMUNITY MENTAL HEALTH SERVICES; DELAYED-ACTION PREPARATIONS; DOCUMENTATION; DRUG MONITORING; FEMALE; HUMANS; IRELAND; MALE; MEDICAL AUDIT; MENTAL DISORDERS; MIDDLE AGED; RURAL HEALTH SERVICES;

EID: 84860452966     PISSN: 13510126     EISSN: 13652850     Source Type: Journal    
DOI: 10.1111/j.1365-2850.2011.01807.x     Document Type: Article

References (37)

1. American Psychiatric Association ed. (2006) Practice guidelines for the treatment of patients with schizophrenia. In: American Psychiatric Association Practice Guidelines for the Treatment of Psychiatric Disorders. Compendium, 2nd edn, pp. 565-747. APA, Arlington, TX.
2. Bloch Y., Mendlovic S., Strupinsky S., etal. (2001) Injections of depot antipsychotic medications in patients suffering from schizophrenia: do they hurt? The Journal of Clinical Psychiatry 62, 855-859.
3. Bowler N., Moss S., Winston M., etal. (2000) An audit of psychiatric case notes in relation to antipsychotic medication and information giving. British Journal of Clinical Governance 5, 212-216.
4. Brad F.H., Gary N. & Tracey P. (2010) The greater of two evils? How people with transformative psychotic experiences view psychotropic medications. Ethical Human Psychology and Psychiatry 12, 44-59.
5. Campbell P. (1996) The future of the mental health system: a survivor perspective. Mental Health Practice 3, 12-17.
6. Canales P.L., Olsen J., Miller A.L., etal. (1999) Role of antipsychotic polypharmacotherapy in the treatment of schizophrenia. CNS Drugs 12, 179-188.
7. Chaplin R. & Kent A. (1998) Informing patients about tardive dyskinesia. The British Journal of Psychiatry 172, 78-81.
8. Gray R. (2007) Shifting the focus: from injection to consultation. In: Progress in Neurology and Psychiatry. Challenging Perceptions of Antipsychotic Long Acting Depot Injections (eds Patel, M.X., Taylor, M., Gray, R., etal.), pp. 8-9. John Wiley & Sons, West Sussex.
9. Gumber R., Abbas M. & Minajagi M. (2010) Monitoring the Metabolic side-effects of atypical antipsychotics. The Psychiatrist 34, 390-395.
10. Higgins A. (2007) Impact of psychotropic medication on sexuality: literature review. British Journal of Nursing 10, 545-550.
11. Hwang S.S.H., Jung C., Ahn Y.M., etal. (2010) The effects of psychopathology on subjective experience of side effects of antipsychotics in patients with schizophrenia. International Clinical Psychopharmacology 25, 62-90.
12. International Diabetes Federation (2006) Available at: (accessed 12 April 2010).
13. Jordan S., Hardy B. & Coleman M. (1999) Medication management: an exploratory study into the role of the community mental health nurse. Journal of Advanced Nursing 29, 1068-1081.
14. Jordan S., Tunnincliffe C. & Sykes A. (2002) Minimizing side-effects: the clinical impact of nurse administered side effect checklists. Journal of Advanced Nursing 37, 155-165.
15. Kim J.H. & Byun H.J. (2010) The relationship between akathisia and subjective tolerability in patients with schizophrenia. International Journal of Neuroscience 120, 507-511.
16. Kim J.H. & Kim M.J. (2009) Association of adverse drug effects with subjective well-being in patients with schizophrenia receiving stable doses of risperidone. Clinical Neuropharmacology 32, 250-253.
17. Knol W., Keijsers C.J.P.W., Jansen P.A.F., etal. (2010) Systematic evaluation of rating scales for drug-induced Parkinsonism and recommendations for future practice. Journal of Clinical Psychopharmacology 30, 57-63.
18. Marland G.R. & Sharkey V. (1999) Depot neuroleptics, schizophrenia and the role of the nurse: is practice evidence based? A review of the literature. Journal of Advanced Nursing 30, 1255-1262.
19. McCann E. (2000) The sexual and relationship needs of people with psychosis: breaking the taboos. Journal of Advanced Nursing 32, 132-138.
20. McCann T.V., Clark E. & Lu S. (2009) Subjective side effects of antipsychotics and medication adherence in people with schizophrenia. Journal of Advanced Nursing 65, 534-543.
21. Millar E., Garland C., Ross F., etal. (1999) Practice nurses and the care of patients receiving depot neuroleptic treatment, views on training, confidence and use of structured assessment. Journal of Advanced Nursing 29, 1454-1461.
22. Millera C.H., Hummera M., Oberbaureb H., etal. (1997) Risk factors for the development of neurolepetic induced akeathisia. European Neuropsychopharmacology 7, 51-55.
23. Morrison P., Gaskill D., Meehan T., etal. (2001) The use of the Liverpool University Neuroleptic Side-Effect Rating Scale (LUNSERS) in clinical practice. Australian and New Zealand Journal of Mental Health Nursing 9, 166-176.
24. National Institute for Clinical Excellence (2002) Guidance on the use of new atypical antipsychotic drugs for the treatment of schizophrenia. Health Technology Appraisal. No. 43. NICE.
25. NHS Plymouth (2009) Depot antipsychotic medication (including risperidone long acting injection). Policy and practice guidelines for use in adults. Version No. 2.7.
26. Patel M.X. & David A.S. (2005) Why aren't depot antipsychotic prescribed more often and what can be done about it? Advances in Psychiatric Treatment 11, 203-213.
27. Phillips L. & McCann E. (2007) The subjective experience of people who regularly receive depot neuroleptic medication in the community. Journal of Psychiatric and Mental Health Nursing 14, 578-586.
28. Rettenbacher M.A., Hofer A., Ebenbichler C., etal. (2010) Prolactin levels and sexual adverse effects in patients with schizophrenia during antipsychotic treatment. Journal of Clinical Psychopharmacology 30, 711-715.
29. Royal College of Psychiatrists (2006) Consensus Statement on High Dose Antipsychotic Medication (CR138). Royal College of Psychiatrists, London.
30. Ryan M.C., Flannagan S., Kinsella U., etal. (2004) The effects of atypical antipsychotic on visceral fat distribution in first line episode drug naïve patients with schizophrenia. Life Sciences 74, 1999-2008.
31. Simpson G.M. & Angus J.W. (1970) A rating scale for extrapyramidal side effects. Acta Psychiatrica Scandinavica 212, 11-19.
32. Taylor D., Paton C. & Kapur S. (2009) The Maudsley Prescribing Guidelines, 10th edn. The South London and Maudsley NHS Foundation Trust and Oxleas NHS Foundation Trust, London.
33. Thakore J.K., Mann J.N., Vlahos I., etal. (2002) Increased visceral fat distribution in drug naïve and drug free patients with schizophrenia. International Journal of Obesity 22, 137-141.
34. United Kingdom Psychiatric Pharmacy Group (UKPPG) (2009) Guidance on the administration to adults of oil-based depot and other long-acting intramuscular antipsychotic injections. Ref incomplete available at (accessed 12 April 2010).
35. Waddell L. & Taylor M. (2008) A new self-rating scale for detecting atypical or second-generation anti-psychotic side effects. Journal of Psychopharmacology 22, 238-243.
36. Walker H. & MacAulay K. (2005) Assessment of the side effects of antipsychotic medication. Nursing Standard 19, 41-46.
37. Williams J.H.G. (1999) Audit of anticholinergic treatment in a psychiatric patient population. Psychiatric Bulletin 23, 22-24.